STAT+：最新心脏病药物试验接连失败，为何应对 AI 炒作保持怀疑
摘要
美国心脏协会年会上公布的两项研究显示，基于遗传学预期的心脏病新药接连落空：Novartis 的 pelacarsen 虽降低了血液中的 lp(a)，却对心脏病发作和中风发生率无效；Novo Nordisk 靶向 IL-6 的抗炎药同样未显示获益。STAT 资深撰稿人 Matthew Herper 据此指出，这类"新技术加速新药上市"的承诺屡屡落空，公众应对 AI 治愈疾病的炒作保持怀疑。
摘要由模型根据原文撰写，以原文为准。
正文 · 原文
Nov. 8, 2026
Senior Writer, Medicine, Editorial Director of Events
The next time someone tells you that artificial intelligence, or any other new technology, is going to cure every disease, point them to the effort to fight heart attacks and strokes, which together are the largest killer in the developed world.
Because again and again, pharmaceutical researchers have learned the same hard lesson: technologies that were supposed to speed new medicines to patients have fallen short. Two studies presented Saturday at the annual meeting of the American Heart Association are a perfect example. A new understanding of genetics was supposed to increase the odds of success – and did anything but.
One study showed that a Novartis drug, pelacarsen, had no effect on the rate of heart attacks and strokes despite lowering a substance in the blood called lp(a), which genetics said should reduce cardiovascular risk. Another large study, from Novo Nordisk, of an anti-inflammatory targeting a protein called IL-6 also showed no benefit.
STAT+ Exclusive Story
Already have an account? Log in
This article is exclusive to STAT+ subscribers
Unlock this article — plus daily coverage and analysis of the pharma industry — by subscribing to STAT+.
Already have an account? Log in
To read the rest of this story subscribe to STAT+.
注意转载授权 · 阅读原文
来源：STAT News · statnews.com
引用原文
Matthew Herper. STAT+: Why the latest heart drug failures should make us all more skeptical of AI hype[EB/OL]. (2026-11-08)[访问日期]. https://www.statnews.com/2026/11/08/heart-drug-failures-lessons-for-artificial-intelligence-from-aha-conference/?utm_campaign=rss.